Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.77 |
| ▸ | PPARG | P37231 | 7/20 | 0.77 |
| ▸ | PPARD | Q03181 | 7/20 | 0.77 |
| ▸ | PPARA | Q07869 | 7/20 | 0.77 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.77 |
| ▸ | TSHR | P16473 | 4/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.77 |
| ▸ | FABP4 | P15090 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | TLR2 | O60603 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.77 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ESR1 | P03372 | 1/20 | 0.77 |
| ▸ | PDE4A | P27815 | 1/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanoic Acid SCHEMBL1031982 | 0.98 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Hexacosanoic Acid SCHEMBL8585366 | 0.98 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Myristic Acid SCHEMBL7533929 | 0.98 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decanoic Acid SCHEMBL31288181 | 0.98 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL28507105 | 0.98 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL28497727 | 0.98 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL2712826 | 0.98 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL29648512 | 0.95 | GPR84 (0.77) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL5078569 | 0.93 | GPR84 (0.74) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL9164233 | 0.93 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021147-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASE | UNIV MICHIGAN REGENTS (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250295712-A1 | COMPOSITIONS AND METHODS FOR MODULATING GUT MICROBIOMES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-09-25 | — | — | US | disclosed |
| US-20240415896-A1 | ANTIMICROBIAL COMPOSITIONS | CORNELL UNIVERSITY | 2024-12-19 | — | — | US | disclosed |
| EP-4475861-A1 | COMPOSITIONS AND METHODS FOR MODULATING GUT MICROBIOMES | The Regents Of The University Of Michigan (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024102831-A2 | MODULATION OF THE GUT MICROBIOME FOR ENHANCEMENT OF GUT AND BRAIN HEALTH | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024073432-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11931386-B2 | Compositions and methods for increasing butyrate production | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-19 | — | — | US | disclosed |
| US-11883444-B2 | Inhibition of enteric infection through the modulation of microbiota | THE UNIVERSITY OF CHICAGO (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230364162-A1 | METHODS AND COMPOSITIONS FOR INTESTINAL INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-16 | — | — | US | disclosed |
| WO-2023154787-A1 | COMPOSITIONS AND METHODS FOR MODULATING GUT MICROBIOMES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20090324547-A1 | Probiotic Oral Health Promoting Product | WIKSTROM, MAUDE (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090285858-A1 | PREVENTION OF ALLERGY IN CHILDREN | FORSKARPATENT I SYD AB (SE) | 2009-11-19 | — | — | US | disclosed |
| EP-1978979-A1 | PROBIOTIC ORAL HEALTH PROMOTING PRODUCT | WIKSTRÖM,, Maude (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080031897-A1 | PREVENTION OF ALLERGY IN CHILDREN | FORSKARPATENT I SYD AB (SE) | 2008-02-07 | — | — | US | disclosed |
| US-20070207169-A1 | EARLY CHILDHOOD INFECTION WITH HUMAN HERPES VIRUS TYPE 6 (HHV-6) AS A PROTECTION AGAINST THE DEVELOPMENT OF IGE SENSITIZATION, ATOPIC DISEASE AND ALLERGY IN YOUNG CHILDREN | FORSKARPATENT I SYD AB (SE) | 2007-09-06 | — | — | US | disclosed |
| WO-2007077210-A1 | PROBIOTIC ORAL HEALTH PROMOTING PRODUCT | WIKSTROEM MAUDE (SE) | 2007-07-12 | — | — | WO | disclosed |
| EP-1796699-A1 | EARLY CHILDHOOD INFECTION WITH HUMAN HERPES VIRUS TYPE 6 (HHV-6) AS A PROTECTION AGAINST THE DEVELOPMENT OF IGE SENSITIZATION, ATOPIC DISEASE AND ALLERGY IN YOUNG CHILDREN. | Forskarpatent i Syd AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1789083-A1 | PREVENTION OF ALLERGY IN CHILDREN | Forskarpatent i Syd AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006031195-A1 | EARLY CHILDHOOD INFECTION WITH HUMAN HERPES VIRUS TYPE 6 (HHV-6) AS A PROTECTION AGAINST THE DEVELOPMENT OF IGE SENSITIZATION, ATOPIC DISEASE AND ALLERGY IN YOUNG CHILDREN. | FORSKARPATENT I SYD AB (SE) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006009501-A1 | PREVENTION OF ALLERGY IN CHILDREN | FORSKAPATENT I SYD AB (SE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021147-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASE | MUC1, O60361, BPGM | GPR84 1481/4885PPARG 2173/4885PPARD 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.